Women benefit most from Mujaro® obesity treatment

Women benefit even more than men from the weight loss offered by Lilly’s weekly obesity treatment, tirzepatide (Munjaro).^®), according to a sub-analysis of clinical trials from the SURMOUNT program presented at the latest congress of the European Association for the Study of Diabetes (EASD). Thus, in all clinical studies analyzed, women achieved greater weight loss with tirzepartide treatment (up to 24.6%) than men (18.1%).

Researchers in this subanalysis examined the mean percentage change in body weight by sex through week 72 (SURMOUNT-1, 2, and 3) or week 88 (SURMOUNT-4). At the time of randomization, women’s mean body weight ranged from 79.6 to 99.8 kg (recorded in SURMOUNT-4 and SURMOUNT-1, respectively), and mean body mass index (BMI) ranged from 30.1 to 38.2 kg/ m2. m2 (in TOP-4 and TOP-1, respectively). The mean weight of men at randomization ranged from 98.6 kg (SURMOUNT-4) to 115.2 kg (SURMOUNT-1), and the mean BMI ranged from 31.4 kg/m2 (SURMOUNT-4) to 37.6 kg/m2 (SURMOUNT-1)1.

In addition to differences in weight loss between sexes, these clinical studies also demonstrated that weight loss was significantly greater with tirzepatide treatment in both men and women compared to placebo, with a reduction ranging from -11.5% to -27.6% in women and women. -8.8% to -18.9% in men (differences relative to placebo in the SURMOUNT-2 and SURMOUNT-3 studies, respectively). Additionally, women in the studies reported more side effects related to gastrointestinal symptoms (mainly nausea and vomiting) than men.

Obesity prevalence and treatment outcomes may differ between men and women due to physiological, sociocultural, and environmental factors. Tirzepatide, a GIP and GLP-1 agonist administered once weekly, has demonstrated efficacy in weight loss in obese or overweight adults with at least one weight-related comorbidity, with or without type 2 diabetes 22 .

The four SURMOUNT clinical trials analyzed in this paper examined the efficacy and safety of tirzepatide compared with placebo over 72 or 88 weeks and included 4,677 obese or overweight adults with at least one medical comorbidity. with weight (2999 women and 1678 men). The purpose of this sub-analysis was to test whether the weight loss effect of tirzepatide varied depending on the gender of the participants. All participants were randomly assigned to receive a dose of drug (5, 10, or 15 mg) or placebo.

This study highlights the benefits of tirzepatide in both sexes, with a particular focus on women. Therefore, according to Dr. Miriam Rubio de Santos, Medical Director of Diabetes and Obesity at Lilly Spain states that “While more research is needed to understand the mechanism by which women may experience greater weight loss in these studies, this subgroup analysis is very interesting as it allows us to study how the drug works in a population that is typically underrepresented, such as women. “.